BMS 986165Alternative Names: BMS-986165
Latest Information Update: 03 Jan 2017
At a glance
- Originator Bristol-Myers Squibb
- Class Antipsoriatics
- Mechanism of Action Interferon type I inhibitors; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PTK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
- Phase I Psoriasis
- Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus